Organoid Single-Cell RNA Sequencing (scRNA-seq) helps researchers analyze the cellular makeup of 3D micro-tissues cell by cell. While standard bulk RNA sequencing provides an average expression profile of the entire sample, scRNA-seq allows you to identify specific cell types, map rare subpopulations, and compare the cellular diversity of your organoid directly against the original donor tissue.
Our service is designed to support translational research and drug discovery teams. We tackle the primary hurdle of organoid scRNA-seq—sample dissociation—to deliver high-quality single-cell data from limited starting materials, helping you validate your models and discover actionable biological mechanisms.
Service Highlights:
Optimized Dissociation: Gentle processing protocols designed to maintain high single-cell viability (>80%) from delicate 3D matrices.
Cell Population Analysis: Direct comparison of cell type proportions between organoid models and parent tissues.
Structured Bioinformatics: Clear, phased data delivery from basic QC and cell clustering to advanced pathway analysis.
The hardest part of organoid single-cell sequencing happens before the sequencing even begins. To use droplet-based microfluidic platforms like 10x Genomics, an intact 3D organoid must be broken down into a suspension of single, living cells. This step is notoriously difficult for 3D models.
Because organoids are embedded in dense extracellular matrices (like Matrigel or BME) and rely on tight cell-to-cell junctions, standard enzymatic digestion used for bulk tissues is often too harsh. Aggressive digestion can rupture delicate cell membranes and cause massive cell death. If the cell viability drops below 80%, the sample will likely fail library preparation due to high ambient RNA contamination (often referred to as "soup"), which ruins the data quality of the surviving cells.
Our service specifically addresses this dissociation challenge. We use mild, optimized dissociation buffers and tightly controlled temperature processing tailored for 3D micro-tissues. This gentle approach effectively dissolves the supportive matrix and loosens cellular junctions while keeping the individual cell membranes completely intact. By maximizing cell survival during extraction, we help ensure that your final sequencing data reflects the true, unbiased cellular composition of your original organoid, rather than just a skewed subpopulation of the most digestion-resistant cells.
Workflow
Organoid scRNA-seq Workflow
We provide an end-to-end service with clear quality control (QC) steps to protect your valuable samples and ensure sequencing success.
Sample Receipt: We check the incoming organoids and matched tissues for appropriate preservation buffer volume, optimal transit temperature, and visual integrity.
Single-Cell Dissociation & QC: We process the 3D samples into a single-cell suspension. QC Checkpoint: We rigorously evaluate cell count and viability using automated counters and fluorometric dyes to ensure they meet the >80% threshold.
Single-Cell Capture & Library Prep: We use microfluidic technology to encapsulate individual cells in droplets with uniquely barcoded beads, followed by mRNA capture and cDNA synthesis. QC Checkpoint: We quantify library fragment size and molarity to ensure even sequencing.
Sequencing: We sequence the validated libraries on high-throughput platforms. QC Checkpoint: We assess raw data for Q30 quality scores and adapter contamination.
Bioinformatics & Data Delivery: We process the raw reads through our custom pipeline and deliver a structured, interactive data report.
Bioinformatics
Structured Bioinformatics Pipeline
We organize our single-cell data analysis into three clear phases, delivering everything from basic data cleaning to complex biological interpretation.
Phase 1: Basic Data Processing
Quality Control: Filtering out ambient RNA, cell doublets (where two cells share one droplet), and low-quality cells. Cells with unusually high mitochondrial gene content are removed, as this typically indicates a dying or ruptured cell.
Alignment & Quantification: Mapping reads to the reference genome and calculating normalized expression profiles for each cell.
Batch Effect Correction: Using specialized integration algorithms (like mutual nearest neighbors) to align multiple datasets. This removes technical noise caused by sequencing on different days, ensuring that observed differences are truly biological.
Phase 2: Cellular Analysis
Dimensionality Reduction (UMAP/t-SNE): High-dimensional transcriptomic data is mathematically reduced into a 2D plot. Cells with similar gene expression profiles are grouped together into visual clusters, helping you easily identify distinct cell types and states.
Marker Gene Identification: Identifying the specific, highly expressed genes that define each cell cluster (e.g., identifying EPCAM for epithelial cells or specific CD markers for immune populations).
Cell Proportion Statistics: Calculating the exact percentage and abundance of different cell types within a given sample.
Phase 3: Biological Interpretation
Differential Gene Expression (DEG): Finding significant gene expression changes between specific cell clusters or across different treatment groups.
Functional Enrichment (GO & KEGG): Mapping the identified DEGs to established databases to understand the active biological processes, cellular components, and metabolic pathways driving the behavior of each cluster.
Concordance Analysis: Quantitatively comparing the cell populations identified in the organoid against those found in the matched parent tissue.
Demo Results
Demo Results: Visualizing Cell Populations
A primary goal of organoid scRNA-seq is to evaluate how closely the 3D model resembles the original donor tissue. Our bioinformatics report includes intuitive visual outputs to help you assess this relationship directly.
Cell Proportion Analysis (Stacked Bar Charts): We provide stacked bar charts comparing the exact ratios of distinct cell types. A reliable organoid model should demonstrate that the proportions of specific lineages—including Epithelial, Mesenchymal, and Immune cells—closely mirror the ratios found in the matched primary tissue. This visual instantly answers the question: "Did certain cell types die off during culture, or is the original tumor ecosystem intact?"
Cell Distribution Concordance (UMAP Overlays): By overlaying the UMAP plots of the organoid cells and the primary tissue cells, we can demonstrate transcriptomic spatial overlap. If the clusters from the in vitro organoid overlap with the in vivoNormal and Tumor clusters from the primary tissue, it suggests the model has successfully preserved the original cellular states and diversity.
Applications
Applications of Organoid scRNA-seq
Single-cell resolution allows researchers to ask specific, complex questions about tumor biology that standard bulk sequencing cannot answer.
Identifying Drug Resistance Mechanisms
Standard viability assays tell you if cells died, but not which cells survived or why. By comparing organoids before and after compound exposure using scRNA-seq, you can identify the exact subpopulation that survives the treatment and isolate the specific transcriptomic pathways driving their acquired resistance.
Discovering Rare Cells
Tumors often harbor low-abundance, high-impact cells, such as specific cancer stem cell (CSC) subsets. Bulk sequencing averages out the expression data, effectively hiding these rare cells. Single-cell analysis allows your team to isolate, identify, and genetically profile these crucial rare populations.
Evaluating Co-Culture Models
If you are co-culturing tumor organoids with immune cells (like CAR-T cells) or cancer-associated fibroblasts, scRNA-seq helps you assess the state and interaction of each distinct cell type within the simulated tumor microenvironment (TME). You can observe immune cell exhaustion markers alongside tumor cell stress responses simultaneously.
Identifying Predictive Biomarkers
By linking distinct, cell-specific gene expression signatures to observed in vitro drug sensitivities, researchers can identify robust transcriptomic biomarkers for future clinical trial patient stratification.
Profiling Strategy
Choosing Your Profiling Strategy: Bulk vs. Single-Cell
Selecting the right sequencing method is critical for both your budget and your specific research endpoints.
When to choose scRNA-seq: You need to find a rare cell type, map exact cellular proportions, evaluate complex co-culture interactions, or understand how a heterogeneous tumor responds to a drug cell-by-cell.
When to choose Bulk RNA-seq: You need to confirm the general genetic profile of the organoid, are screening many compounds across a largely homogenous cell population, or require a more budget-friendly approach for large sample cohorts.
Single-cell transcriptomics requires living, highly viable cells. Proper sample preparation and strict cold-chain shipping are essential to prevent cell death before the sample even reaches our laboratory.
Paired Samples
We highly recommend submitting paired samples (the organoid model and its matched parental tissue of origin). This is necessary if you want to perform cell proportion comparisons and distribution concordance analysis to validate your model.
Submission Parameters
Sample Type
Minimum Input
Container / Buffer
Shipping Conditions
Fresh Organoids
0.6g (approx. 3 soybeans)
Tissue preservation buffer
2-8°C with ice packs. Do not freeze.
Needle Biopsies
≥3 needles (outer diameter ≥1.2mm)
Tissue preservation buffer
2-8°C with ice packs. Ship immediately.
Matched Primary Tissue
>0.5g (if available)
Tissue preservation buffer
2-8°C with ice packs.
Important: Do not attempt to dissociate the organoids into single cells in your own laboratory prior to shipping. Freeze-thawing a single-cell suspension drastically reduces cell viability, destroys membrane integrity, and often leads to complete project failure.
Case Study
Case Study: Analyzing Drug Resistance in Hepatobiliary Organoids
The following peer-reviewed study illustrates how single-cell transcriptomic profiling can be powerfully applied to complex 3D models to uncover novel biological mechanisms.
Hepatobiliary tumors are notoriously heterogeneous, making effective targeted therapies difficult to develop and predict. Researchers established donor-derived 3D models to replicate this specific diversity in vitro to study why certain tumors resist treatment.
The research team successfully established hepatobiliary tumor organoids from multiple donor samples. To analyze the cellular makeup of these models and evaluate inter- and intratumoral heterogeneity, they utilized single-cell RNA sequencing (scRNA-seq).
As shown in Figure 2 of the study, the scRNA-seq analysis successfully identified distinct cellular sub-clusters within the organoids. The UMAP plots revealed significant variations in transcriptional programs related to the cell cycle, epithelial states, and hypoxia. More importantly, the single-cell data helped the team identify specific stem-like cells (CSCs) and unique metabolic circuits that act as underlying drivers of drug resistance.
The scRNA-seq data provided definitive evidence that these organoid models preserved the diverse cellular ecosystem of the original tissues. The deep profiling allowed the researchers to move beyond simple viability assays and map the exact cellular sub-populations responsible for drug resistance, supporting their use as robust platforms for precision oncology research.
Q1. We cultured organoids according to established protocols, but their morphology looks different. Does this mean the model failed?
Not necessarily. Differences in donor genetic background, cytokine batches, or culture media can easily alter physical morphology. Morphology is a useful initial check, but it doesn't tell the whole story. ScRNA-seq can help verify if the expected cell types and proper cellular proportions are actually present in the model, providing an objective evaluation regardless of outward shape.
Q2. Why is organoid dissociation so difficult?
Standard enzymatic digestion is often too harsh for the dense matrices used in organoid culture, leading to cell death. Achieving the >80% cell viability required for droplet-based microfluidic platforms like 10x Genomics requires gentle, highly optimized dissociation protocols specifically tailored for 3D structures.
Q3. Can I customize the bioinformatics pipeline?
Yes. Beyond our standard basic processing and cellular analysis phases, our team can perform deep sub-clustering on specific cell lineages. For example, we can isolate only the immune cells in a co-culture model or run trajectory/pseudotime analysis to study cellular development and differentiation.
Q4. What happens if my sample viability is too low upon arrival?
If our initial QC shows cell viability below the required threshold (typically <80%), we will immediately pause the project and contact you. Proceeding with a high percentage of dead or dying cells leads to high ambient RNA contamination, which skews data and wastes sequencing resources. This is why strict adherence to our cold-chain shipping guidelines is critical.
Q5. How do you handle "batch effects" when analyzing multiple samples?
Batch effects are common in scRNA-seq, especially when samples are prepared or sequenced on different days. We use advanced data integration algorithms during the "Basic Data Processing" phase to align datasets computationally. This helps remove technical noise while strictly preserving the true biological differences between your experimental samples.
Disclaimer: All services and products detailed on this page are intended for Research Use Only (RUO). They are not intended for use in diagnostic procedures, clinical decision-making, or any therapeutic applications.
For research purposes only, not intended for clinical diagnosis, treatment, or individual health assessments.
Inquiry
x
Quote Request
CD Genomics is transforming biomedical potential into precision insights through seamless sequencing and advanced bioinformatics.
